
Angela Ceribelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/55746/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Clinical Reviews in Allergy and Immunology, 2017, 52, 1-19.	2.9	286
2	Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Research and Therapy, 2012, 14, R97.	1.6	124
3	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	1.0	118
4	Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera. Journal of Immunological Methods, 2016, 433, 1-5.	0.6	109
5	MicroRNAs in systemic rheumatic diseases. Arthritis Research and Therapy, 2011, 13, 229.	1.6	107
6	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. Journal of Autoimmunity, 2020, 109, 102442.	3.0	104
7	Malignancies in Italian Patients with Systemic Sclerosis Positive for Anti-RNA Polymerase III Antibodies. Journal of Rheumatology, 2011, 38, 1329-1334.	1.0	94
8	Lessons learned from twins in autoimmune and chronic inflammatory diseases. Journal of Autoimmunity, 2017, 83, 51-61.	3.0	91
9	MicroRNAs in rheumatoid arthritis. FEBS Letters, 2011, 585, 3667-3674.	1.3	88
10	The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Autoimmunity Highlights, 2014, 5, 9-19.	3.9	83
11	MicroRNAs and autoimmunity. Current Opinion in Immunology, 2012, 24, 686-691.	2.4	75
12	MicroRNA-146a in autoimmunity and innate immune responses. Annals of the Rheumatic Diseases, 2013, 72, ii90-ii95.	0.5	74
13	Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus, 2009, 18, 735-739.	0.8	68
14	Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clinical and Experimental Rheumatology, 2014, 32, 891-7.	0.4	66
15	Systemic rheumatic diseases: From biological agents to small molecules. Autoimmunity Reviews, 2019, 18, 583-592.	2.5	64
16	Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. Lupus, 2008, 17, 727-732.	0.8	58
17	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Realâ€Life Setting. Arthritis and Rheumatology, 2020, 72, 1314-1324.	2.9	58
18	Anti-Th/To Are Common Antinucleolar Autoantibodies in Italian Patients with Scleroderma. Journal of Rheumatology, 2010, 37, 2071-2075.	1.0	52

Angela Ceribelli

#	Article	IF	CITATIONS
19	Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmunity Reviews, 2008, 8, 104-106.	2.5	50
20	Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clinical Rheumatology, 2011, 30, 1333-1339.	1.0	50
21	Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmunity Reviews, 2009, 8, 580-584.	2.5	46
22	Differential Reactivity to IMPDH2 by Anti-rods/rings Autoantibodies and Unresponsiveness to Pegylated Interferon-alpha/Ribavirin Therapy in US and Italian HCV Patients. Journal of Clinical Immunology, 2013, 33, 420-426.	2.0	46
23	Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clinical Rheumatology, 2017, 36, 469-475.	1.0	45
24	A case of psoriatic arthritis triggered by SARS-CoV-2 infection. Rheumatology, 2021, 60, e21-e23.	0.9	45
25	Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15years. Autoimmunity Reviews, 2016, 15, 162-166.	2.5	44
26	The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review. Clinical Reviews in Allergy and Immunology, 2017, 52, 58-70.	2.9	41
27	Autoantibodies to survival of motor neuron complex in patients with polymyositis: Immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins. Arthritis and Rheumatism, 2011, 63, 1972-1978.	6.7	40
28	Cardiological features in idiopathic inflammatory myopathies. Journal of Cardiovascular Medicine, 2010, 11, 906-911.	0.6	38
29	Safety issues and concerns of new immunomodulators in rheumatology. Expert Opinion on Drug Safety, 2015, 14, 389-399.	1.0	34
30	Primary Biliary Cirrhosis-related Autoantibodies in a Large Cohort of Italian Patients with Systemic Sclerosis. Journal of Rheumatology, 2011, 38, 2180-2185.	1.0	33
31	Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic <i>Lupus erythematosus</i> . Autoimmunity, 2013, 46, 363-368.	1.2	33
32	Anti-RNA Polymerase III Antibodies as a Risk Marker for Early Gastric Antral Vascular Ectasia (GAVE) in Systemic Sclerosis. Journal of Rheumatology, 2010, 37, 1544.1-1544.	1.0	31
33	PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. Clinical Rheumatology, 2016, 35, 501-505.	1.0	28
34	Autoantibodies to Argonaute 2 (Su Antigen). Advances in Experimental Medicine and Biology, 2013, 768, 45-59.	0.8	26
35	Positive Correlation of STAT1 and miR-146a with Anemia in Patients with Systemic Lupus Erythematosus. Journal of Clinical Immunology, 2014, 34, 171-180.	2.0	26
36	Personalized medicine in rheumatology: the paradigm of serum autoantibodies. Autoimmunity Highlights, 2017, 8, 10.	3.9	25

ANGELA CERIBELLI

#	Article	IF	CITATIONS
37	"Disease knowledge index―and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. Joint Bone Spine, 2019, 86, 475-481.	0.8	25
38	Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay. Arthritis Research and Therapy, 2013, 15, R50.	1.6	24
39	Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset. Arthritis Research and Therapy, 2014, 16, R23.	1.6	24
40	Lupus T cells switched on by DNA hypomethylation via microRNA?. Arthritis and Rheumatism, 2011, 63, 1177-1181.	6.7	23
41	Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. Clinical Reviews in Allergy and Immunology, 2023, 64, 412-430.	2.9	23
42	Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis. Arthritis Research and Therapy, 2012, 14, R79.	1.6	22
43	Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis. Frontiers in Immunology, 2021, 12, 622770.	2.2	21
44	Medical cannabis and cannabinoids in rheumatology: where are we now?. Expert Review of Clinical Immunology, 2019, 15, 1019-1032.	1.3	20
45	Hepatitis C virus infection and primary Sjögren's Syndrome: A clinical and serologic description of 9 patients. Autoimmunity Reviews, 2008, 8, 92-94.	2.5	19
46	International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. Arthritis Research and Therapy, 2012, 14, R2.	1.6	19
47	Elevated signal transducers and activators of transcription 1 correlates with increased C-C motif chemokine ligand 2 and C-X-C motif chemokine 10 levels in peripheral blood of patients with systemic lupus erythematosus. Arthritis Research and Therapy, 2014, 16, R20.	1.6	19
48	Nailfold videocapillaroscopy and serum VEGF levels in scleroderma are associated with internal organ involvement. Autoimmunity Highlights, 2016, 7, 5.	3.9	19
49	ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY. Endocrine Practice, 2018, 24, 405-410.	1.1	19
50	Reference standards for the detection of anti-mitochondrial and anti-rods/rings autoantibodies. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1789-1798.	1.4	18
51	Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options. Clinical and Experimental Rheumatology, 2017, 35, 303-308.	0.4	16
52	Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). Autoimmunity, 2011, 44, 90-97.	1.2	15
53	Detection of anti-mitochondrial antibodies by immunoprecipitation in patients with systemic sclerosis. Journal of Immunological Methods, 2018, 452, 1-5.	0.6	15
54	Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population. International Journal of Cardiology, 2020, 300, 209-213.	0.8	15

Angela Ceribelli

#	Article	IF	CITATIONS
55	Environmental triggers for connective tissue disease. Current Opinion in Rheumatology, 2021, Publish Ahead of Print, 514-521.	2.0	14
56	Echocardiographic Evaluation of Asymptomatic Patients Affected by Rheumatoid Arthritis. Journal of Investigative Medicine, 2012, 60, 1204-1208.	0.7	13
57	Psoriatic arthritis induced by anti-PD1 and treated with apremilast: a case report and review of the literature. Immunotherapy, 2020, 12, 549-554.	1.0	13
58	Seronegative reactive spondyloarthritis and the skin. Clinics in Dermatology, 2015, 33, 531-537.	0.8	12
59	Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction. Lupus, 2015, 24, 442-447.	0.8	12
60	Common Pathways of Autoimmune Inflammatory Myopathies and Genetic Neuromuscular Disorders. Clinical Reviews in Allergy and Immunology, 2012, 42, 16-25.	2.9	11
61	Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others. Clinical Reviews in Allergy and Immunology, 2022, 63, 210-239.	2.9	11
62	Complement Cascade in Systemic Lupus Erythematosus. Annals of the New York Academy of Sciences, 2009, 1173, 427-434.	1.8	10
63	Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies. Journal of Translational Autoimmunity, 2020, 3, 100049.	2.0	9
64	Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study. Arthritis Research and Therapy, 2011, 13, R73.	1.6	8
65	A new immunoprecipitation-real time quantitative PCR assay for anti-Th/To and anti-U3RNP antibody detection in systemic sclerosis. Arthritis Research and Therapy, 2012, 14, R128.	1.6	8
66	Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis. Clinical and Experimental Immunology, 2021, 205, 142-149.	1.1	8
67	Elastic properties of the ascending aorta in patients with rheumatoid arthritis. International Journal of Cardiology, 2011, 150, 368-369.	0.8	7
68	Coexistence of anti-RNA polymerase III and anti-U1RNP antibodies in patients with systemic lupus erythematosus: two cases without features of scleroderma. Lupus, 2012, 21, 68-74.	0.8	6
69	Antibodies to Rods and Rings. , 2014, , 161-168.		6
70	Immunodiagnosis of Autoimmune Myopathies. , 0, , 878-887.		6
71	Epigenetic Methods and Twin Studies. Advances in Experimental Medicine and Biology, 2020, 1253, 95-104.	0.8	6
72	DNA Methylation Signature in Monozygotic Twins Discordant for Psoriatic Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 778677.	1.8	6

ANGELA CERIBELLI

#	Article	IF	CITATIONS
73	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations. Clinical Reviews in Allergy and Immunology, 2022, 63, 240-250.	2.9	6
74	Atypical clinical presentation of a subset of patients with anti-RNA polymerase III - non-scleroderma cases associated with dominant RNA polymerase i reactivity and nucleolar staining. Arthritis Research and Therapy, 2011, 13, R119.	1.6	5
75	Antigen Reactivity and Clinical Significance of Autoantibodies Directed Against the Pyruvate Dehydrogenase Antigen Complex in Patients With Connective Tissue Disease. Frontiers in Immunology, 2022, 13, 822996.	2.2	5
76	Anti-Cardiolipin and Anti-beta2-Glycoprotein I Antibodies: Performance of New Commercial ELISA Kits. Annals of the New York Academy of Sciences, 2007, 1109, 531-537.	1.8	4
77	Clinical significance of rare serum autoantibodies in rheumatic diseases: a systematic literature review. Journal of Laboratory and Precision Medicine, 2018, 3, 89-89.	1.1	3
78	Humoral Response Against LLâ€37 in Psoriatic Disease: Comment on the Article by Yuan et al. Arthritis and Rheumatology, 2019, 71, 1964-1965.	2.9	3
79	Aortic stiffness and left ventricular hypertrophy in rheumatoid arthritis: Comment on the article by Rudominer et al. Arthritis and Rheumatism, 2009, 60, 2852-2853.	6.7	2
80	Role of environmental factors in autoantibody production - importance of a detailed analysis in a small cohort. Arthritis Research and Therapy, 2012, 14, 109.	1.6	2
81	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. Clinical Reviews in Allergy and Immunology, 2022, 62, 346-353.	2.9	2
82	Autoimmune Polyendocrine Syndromes. , 2008, , 265-269.		2
83	Anti-MJ/NXP-2 antibodies are the most common specifcity in a cohort of adult caucasian patients with dermatomyositis. Annals of the Rheumatic Diseases, 2012, 71, A49.2-A49.	0.5	1
84	Suspected and unsuspected factors in the multifaceted immunopathology of viral hepatitis. Seminars in Immunopathology, 2013, 35, 1-5.	2.8	1
85	The Interplay of Epigenetics and Epidemiology in Autoimmune Diseases. , 2015, , 139-148.		1
86	FRI0199â€EFFECTIVENESS AND SAFETY OF BELIMUMAB IN PATIENTSWITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC STUDY. , 2019, , .		1
87	Comment on: Inflammatory myopathy associated with anti-mitochondrial antibodies: A distinct phenotype with cardiac involvement. Seminars in Arthritis and Rheumatism, 2019, 48, e23-e24.	1.6	1
88	Autoantibodies to Survival of Motor Neuron (SMN) Complex. , 2014, , 139-144.		0
89	Antinuclear Antibodies. , 2014, , 129-137.		0
90	Antimitochondrial Antibodies. , 2014, , 485-490.		0

#	Article	IF	CITATIONS
91	FRI0316â€SERUM ANTI-MITOCHONDRIAL ANTIBODIES IN SYSTEMIC SCLEROSIS RECOGNIZE VARIABLE PYRUV⁄ DEHYDROGENASE COMPLEX ANTIGENS. , 2019, , .	ATE	0
92	FRI0330â€MALIGNANCIES IN SYSTEMIC SCLEROSIS PATIENTSWITH ANTI-PM/SCL ANTIBODIES: AN EUSTAR CAS CONTROL STUDY. , 2019, , .	ξE-	0
93	SAT0267â€SERUM ANTI-HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN ANTIBODY CHARACTERIZES SYSTEMIC SCLEROSIS WITH ANTI CENTROMERE ANTIBODY AND SEVERE RAYNAUD'S PHENOMENON WITH DIGITAL ULCERS. , 2019, , .		0
94	The Geoepidemiology of Autoimmune Liver Disease. , 2014, , 27-43.		0
95	Additional Organs Involved in Antiphospholipid Syndrome: Eye, Ear-Nose-Throat, Lung, Gastroenteric System, Endocrine Glands. Rare Diseases of the Immune System, 2015, , 163-168.	0.1	0
96	Sex and autoimmune disease: Four mechanisms pointing at women. Mediterranean Journal of Rheumatology, 2019, 30, 162.	0.3	0